| Age (years) |
69 (55-85) |
84 (69-85) |
63 (54-76) |
0.08 |
| Women (%) |
10 (33.3) |
5 (27.8) |
5 (41.7) |
0.46 |
| McCabe classification (%) |
0.44 |
|
0: no fatal underlying disease |
19 (63.3) |
9 (75) |
10 (55.6) |
|
|
1: life expectancy ≤5 years |
11 (36.7) |
3 (25) |
8 (44.4) |
|
|
2: life expectancy <1 year |
0 |
0 |
0 |
|
| Patient's location before ICU admission (%) |
0.66 |
|
Home |
15 (50) |
7 (58.3) |
8 (44.4) |
|
|
Ward |
15 (50) |
5 (41.7) |
10 (55.6) |
|
| Pre-existing cardiac insufficiency (%) |
6 (20) |
3 (25) |
3 (16.7) |
0.66 |
| Surgical admission (%) |
10 (33.3) |
4 (33.3) |
6 (31.6) |
0.99 |
| Weight (kg) |
68 (65-79) |
67 (61-73) |
70 (66-79) |
0.29 |
| SAPS II at admission |
53 (39-64) |
57 (38-80) |
52 (39-60) |
0.45 |
| SOFA score at admission |
10 (6-12) |
10 (3-12) |
10 (8-12) |
0.77 |
|
Characteristics of shock
|
|
| SIRS criteria at admission |
|
|
Temperature (°C) |
37.3 (36.2-38.3) |
36.5 (36.2-38.0) |
37.4 (36.1-38.3) |
|
|
Heart rate (bpm) |
108 (90-121) |
103 (85-111) |
111 (101-124) |
|
|
Leucocyte count (×109/L) |
13.9 (10.3-20.1) |
14.6 (13.5-16.9) |
11.9 (10.2-22.4) |
|
| Tissue hypoperfusion/organ dysfunction |
|
|
PaO2/FiO2 (mm Hg) |
189 (121-273) |
152 (74-191) |
258 (171-300) |
0.02 |
|
Urinary output (mL/24 h) |
950 (400-1630) |
900 (400-1620) |
1175(480-1750) |
|
|
Lactate (mmol/L) |
2.1 (1.3-4) |
2.7 (2.1-3.3) |
1.9 (1.1-4.7) |
|
|
Platelet counts (×109/L) |
232 (150 -311) |
263 (172-325) |
200 (130-303) |
|
|
Haematocrit (%) |
33.6 (31.3-38) |
34.3 (28.8 -39.6) |
33.7 (31.4 -37.1) |
|
|
Glasgow Coma Score |
9 (3-15) |
10 (3-14) |
9 (3-15) |
|
| Shock criteria |
|
|
Systolic blood pressure (mm Hg) |
90 (84-98) |
88 (85-92) |
91 (84-99) |
|
|
Mean arterial blood pressure (mm Hg) |
63 (59-72) |
63 (57-73) |
64 (60-68) |
|
|
Catecholamine requirements (%) |
30 (100) |
12 (100) |
18 (100) |
|
|
|
Epinephrine (%) |
7 (23.3) |
2 (16.7) |
5 (27.8) |
|
|
|
Norepinephrine (%) |
20 (66.7) |
8 (66.7) |
12 (66.7) |
|
|
|
Dobutamine and norepinephrine (%) |
2 (6.7) |
1 (8.3) |
1 (5.5) |
|
|
|
Epinephrine and norepinephrine (%) |
1 (3.3) |
1 (8.3) |
0 (0.0) |
|
|
From onset of shock to inclusion
|
|
Duration of shock (days) |
4 (3-6) |
4 (3-7) |
4 (3-5) |
|
|
SOFA max |
13 (11-15) |
13 (12-16) |
12 (10-13) |
0.10 |
|
SOFA inclusion |
2 (1-4) |
2 (1-5) |
2 (0-3) |
0.31 |
|
Renal replacement therapy (%) |
7 (23.3) |
4 (33.3) |
3 (16.7) |
0.39 |
|
Mechanically ventilated patients (%) |
28 (93.3) |
12 (100) |
16 (88.9) |
0.7 |
|
Duration of mechanical ventilation |
12 (6-18) |
16 (10-21) |
7 (4-13) |
0.12 |
|
P/F min |
152 (91-243) |
104 (60-168) |
211 (105-300) |
0.028 |
|
Plasma bilirubin level max (µmol/l) |
15 (9-23) |
10 (9-14) |
21 (12-26) |
0.065 |
|
Cumulative doses of catecholamines requirement (mg) |
61 (34-170) |
114 (35-174) |
51 (34-115) |
0.4 |
|
Duration of sedation (days) |
5 (2-9) |
9 (4-19) |
4 (2-6) |
0.08 |
|
Delay from ICU admission to inclusion (days) |
15 (10-23) |
18 (11-29) |
12 (10-21) |
0.31 |
|
Delay from onset of shock to inclusion (days) |
12 (10-19) |
14 (10-20) |
12 (10-18) |
0.73 |
|
Delay from end of shock to inclusion (days) |
8 (5-11) |
8 (6-10) |
7 (5-15) |
0.47 |
